Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electroporation therapy enters Phase II trials:

This article was originally published in Clinica

Executive Summary

The FDA has agreed to let US company Genetronics Biomedical begin Phase II clinical trials for electroporation therapy in advanced head and neck cancer patients in whom standard treatment has failed. Electroporation allows easier and more efficient delivery of pharmaceuticals or genes by using an electric field to open the pores in human cells.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel